Viele konkrete Handlungsempfehlungen

'It is an orientation aid on the way to a better care situation,' explained Prof Dr Stephan Baldus, Director of the Medical Clinic III for Internal Medicine at the University Hospital of Cologne, who took part as patron in the presentation of the recently published new white paper 'Prevention of Cardiovascular Diseases - Care Situation in Germany' (1). The white paper, financed by Novo Nordisk Pharma, pursues 'a scientific approach, is neutral and independent of products', as Hans-Holger Bleß (_fbeta) emphasised at the presentation of the white paper's findings. The third speaker at the book presentation, Prof Dr Ulrich Laufs, Clinic and Polyclinic for Cardiology at Leipzig University Hospital and co-author of the White Paper, gave an indication of why Novo Nordisk is involved in this area. He said: 'We need to take a closer look at cardiovascular inflammation as a significant risk factor. This is a great opportunity for more effective treatment of cardiovascular diseases.'